

# Evaluation of intrauterine balloon tamponade efficacy with condom catheter in the severe postpartum hemorrhage management in Benin and Mali

|                                        |                                                       |                                                                                                              |
|----------------------------------------|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>05/05/2013   | <b>Recruitment status</b><br>No longer recruiting     | <input checked="" type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol            |
| <b>Registration date</b><br>09/09/2013 | <b>Overall study status</b><br>Completed              | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                       |
| <b>Last Edited</b><br>27/02/2017       | <b>Condition category</b><br>Pregnancy and Childbirth | <input type="checkbox"/> Individual participant data<br><input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

The decrease of maternal death is one of the millennium goals defined by the World Health Organisation (WHO). Bleeding after delivery (postpartum hemorrhage) is the first cause of maternal death in countries with low incomes, and in particular in sub-Saharan African countries. Intrauterine tamponade with a condom catheter is a possible treatment for postpartum hemorrhage in these countries. The aim of this study is to demonstrate that the intrauterine tamponade by condom catheter reduces death and severe disease rates in cases of severe postpartum hemorrhage.

### Who can participate?

All women giving birth in one of the centers participating in the study and presenting a severe postpartum hemorrhage, not responding to the first-line of treatment (oxytocine + uterine massage + uterine revision). Women under the legal age will be able to participate in this study after authorization of a legal representative.

### What does the study involve?

Patients are randomly allocated to one of two groups. One group receives intrauterine balloon tamponade by condom catheter and usual treatment (misoprostol) and the other receives usual treatment (misoprostol alone).

### What are the possible benefits and risks of participating?

The intrauterine balloon tamponade seems to be a promising technique in the treatment of the postpartum hemorrhage. In order to avoid any loss of luck for the patients participating in the study, the intrauterine balloon tamponade will be given to patients belonging to the group receiving usual treatment. There are no risks linked to the treatment by misoprostol, except the minor side effects of this product: nausea, vomiting, shiver, fever and abdominal pain (all of these are specified in the information note for the patients). The potential risk identified for the intrauterine balloon tamponade is a risk of infection. However, among 239 cases of intrauterine

balloon tamponade tested in low-income countries, no case of infection was indicated. Furthermore, this study plans a preventive treatment by antibiotics to prevent this risk of infection.

Where is the study run from?

There are seven centers taking part in this study:

Four in Cotonou:

1. Reference health center: Hôpital Mère-Enfant de la Lagune (HOMEL)
2. District hospital: Abomey-Calavi hospital
3. District hospital: Menontin hospital
4. Peripheral maternity of Missessin

Three in Bamako, Mali:

1. Reference health center of Commune V
2. Community health center of Sabalibougou I
3. Community health center of Torokorobougou

When is the study starting and how long is it expected to run for?

May 2013 to December 2015

Who is funding the study?

1. Institut de Recherche pour le Développement (IRD) (France)
2. Muskoka Fund for operational research, UNICEF, Regional Office for Central and Western Africa

Who is the main contact?

1. Mrs Cecile Bodin (cecile.bodin@gmail.com)
2. Dr Alexandre Dumont (alexandre.dumont@ird.fr)

## Contact information

### Type(s)

Scientific

### Contact name

Dr Alexandre Dumont

### ORCID ID

<https://orcid.org/0000-0003-3826-0193>

### Contact details

IRD UMR 216

Faculté de pharmacie

4 avenue de l'observatoire

Paris

France

75006

-

[alexandre.dumont@ird.fr](mailto:alexandre.dumont@ird.fr)

## Additional identifiers

**Protocol serial number**

TIUHPPI v15/04/2013

## **Study information**

**Scientific Title**

Evaluation of intrauterine balloon tamponade efficacy with condom catheter and misoprostol (usual treatment) compared to misoprostol alone in the severe postpartum management hemorrhage management in Benin and Mali: a randomized controlled trial

**Acronym**

Condom PPH

**Study objectives**

The aim of this study is to demonstrate that the intrauterine tamponade by condom catheter reduces mortality and severe morbidity rate in case of severe postpartum hemorrhage.

The hypothesis is that the mortality and severe morbidity rate (recourse to an invasive surgery) should reach 25% in the control group and 6% in the intervention group.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

1. France: Professional ethics and Ethics Consultative Committee of the Research Institute for Development (CCDE IRD), 29/01/2013
2. Mali: Ethics Committee of the Faculty of Medicine, Pharmacy and Odonto-Stomatology (FMPOS), 19/04/2013, ref: 2013/35/CE/FMPOS
3. Benin: Ethics and Research Committee of the Institute of the Biomedical Applied Sciences (ISBA) of Benin, 16/11/2012

**Study design**

International randomized controlled trial multicenter open-label in two parallel groups

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Gynecology-obstetrical/severe postpartum hemorrhage

**Interventions**

The first line of post-partum hemorrhage (PPH) management is an injection of oxytocin + the realisation of an uterine massage and a uterine revision. These 3 treatments have to be realised jointly. Thus, if neither the injection of oxytocin, nor the uterine massage and the uterine revision allows to stop the PPH, the second line of PPH management has to be realized (administration of misoprostol or misoprostol + condom catheter tamponade).

Women presenting a postpartum hemorrhage resistant to oxytocin and first line laborers (uterine massage + uterine revision), will be randomized in order to receive:

1. The usual treatment to the posology of 5 tablets of Misoprostol 200 µg (intra-rectal) or 3 tablets of Misoprostol 200 µg (sub-lingual) immediately associated with an intrauterine balloon tamponade by condom-catheter
2. Only the usual treatment to the posology of 5 tablets of Misoprostol 200 µg (intra-rectal) or 3 tablets of Misoprostol 200 µg (sub-lingual)

### **Intervention Type**

Drug

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Misoprostol

### **Primary outcome(s)**

The primary outcome is a composite outcome: individual recourse to an invasive surgery (arterial ligatures, uterine compressive sutures, hysterectomy of haemostasis) and/or maternal death before the hospital release

### **Key secondary outcome(s)**

Each element of the composite primary outcome is related to the point 1 and 2 only. So the secondary outcomes are formed by the 2 elements of the primary outcome measured separately and we will also measure three other outcomes: bleedings > 1000 mL, necessity of a transfusion, necessity of a transfer.

1. Invasive intervention rate (arterial ligatures, uterine compressive sutures or hysterectomy of haemostasis): number of women having received an invasive intervention divided by the number of women included
2. Hospital maternal mortality rate (number of women included in the study and died before the hospital release divided by the number of inclusive women)
3. Bleeding > 1000 mL.
4. Necessity of a transfusion
5. Necessity of a transfer

### **Completion date**

31/12/2015

## **Eligibility**

### **Key inclusion criteria**

1. Having given birth by vaginal way, in one of the selected establishments
2. After 28 weeks of amenorrhea, or foetus > 1000 g
3. Presenting a HPPI resisting the oxytocine and the first-line laborers (uterine massage + uterine revision)
4. Having given its oral consent

### **Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

Female

**Key exclusion criteria**

1. Having given birth by caesarian
2. Presenting a contraindication or an allergy known about prostaglandins
3. Presenting an allergy to latex
4. Presenting a clinical Chorioamnionitis
5. Presenting a secondary postpartum hemorrhage, cervico-vaginal tears without uterine bleeding, an uterine break, or a placenta accreta

**Date of first enrolment**

14/10/2013

**Date of final enrolment**

31/12/2015

**Locations****Countries of recruitment**

Benin

Mali

**Study participating centre**

**Reference health center: Hôpital Mère-Enfant de la Lagune (HOMEL)**

Cotonou

Benin

-

**Study participating centre**

**District hospital: Abomey-Calavi Hospital**

Cotonou

Benin

-

**Study participating centre**

**District hospital: Menontin Hospital**

Cotonou

Benin

-

**Study participating centre**

**Peripheral maternity of Missessin**

Cotonou

Benin

-

**Study participating centre**

**Reference health center of Commune V**

Bamako

Mali

-

**Study participating centre**

**Community health center of Sabalibougou I**

Bamako

Mali

-

**Study participating centre**

**Community health center of Torokorobougou**

Bamako

Mali

-

## **Sponsor information**

**Organisation**

Institute of Research for Development (Institut de Recherche pour le Développement) (IRD)

**ROR**

<https://ror.org/05q3vnk25>

## **Funder(s)**

**Funder type**

Research organisation

**Funder Name**

Institute of Research for Development (Institut de Recherche pour le Développement) (IRD), Paris (France) (ref: TIUHPPI)

**Funder Name**

Muskoka Fund for operational research, UNICEF, Regional Office for Central and Western Africa

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

The datasets generated during and/or analysed during the current study are/will be available upon request from Dr Alexandre Dumont ([alexandre.dumont@ird.fr](mailto:alexandre.dumont@ird.fr))

**IPD sharing plan summary**

Available on request